1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT Letermovir - Hematologic Malignancy | Phase 3 | Active not recruiting | Ruijin Hospital | 250 | 2024-07-01 | 2025-12-15 |
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms by Site (1)
letermovir (1)
Ruijin Hospital (1)
China (1)